Dopamine response to psychosocial stress in chronic cannabis users: A PET study with 11 C-(+)-PHNO

Neuropsychopharmacology

Volumn 38, Issue 4, 2013, Pages 673-682

  Mizrahi, Romina ^a,b   Suridjan, Ivonne ^a   Kenk, Miran ^a   George, Tony P ^a,b   Wilson, Alan ^a,b   Houle, Sylvain ^a,b   Rusjan, Pablo ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

11C (+) PHNO; cannabis use disorder; dopamine; positron emission tomography; psychosocial stress

Indexed keywords

CANNABIS; CARBON 11; DOPAMINE; NAXAGOLIDE;

ADULT; ARTICLE; ASSOCIATION; BRAIN REGION; CANNABIS ADDICTION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; FEMALE; HUMAN; LABORATORY TEST; MALE; MENTAL STRESS; NIGRONEOSTRIATAL SYSTEM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSORIMOTOR FUNCTION; VALIDATION PROCESS;

ADULT; CARBON RADIOISOTOPES; DOPAMINE; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; OXAZINES; POSITRON-EMISSION TOMOGRAPHY; SOCIAL ENVIRONMENT; STRESS, PSYCHOLOGICAL; YOUNG ADULT;

EID: 84873739013     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.232     Document Type: Article

References (63)

1. Andreasson S, Allebeck P, Engstrom A, Rydberg U (1987). Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2: 1483-1486.
2. Bauman A, Phongsavan P (1999). Epidemiology of substance use in adolescence: prevalence, trends and policy implications. Drug Alcohol Depend 55: 187-207.
3. Boileau I, Payer D, Houle S, Behzadi A, Rusjan PM, Tong J et al (2012). Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(\+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci 32: 1353-1359.
4. Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD et al (2009). Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 34: 759-766.
5. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A et al (1997). Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94: 2569-2574.
6. Buckner JD, Crosby RD, Wonderlich SA, Schmidt NB (2012). Social anxiety and cannabis use: an analysis from ecological momentary assessment. J Anxiety Disord 26: 297-304.
7. Chen JP, Paredes W, Li J, Smith D, Lowinson J, Gardner EL (1990). Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology (Berl) 102: 156-162.
8. Davila V, Yan Z, Craciun LC, Logothetis D, Sulzer D (2003). D3 dopamine autoreceptors do not activate G-protein-gated inwardly rectifying potassium channel currents in substantia nigra dopamine neurons. J Neurosci 23: 5693-5697.
9. Diaz J, Pilon C, Le Foll B, Gros C, Triller A, Schwartz JC et al (2000). Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci 20: 8677-8684.
10. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT et al (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29: 1558-1572.
11. Dressendorfer RA, Kirschbaum C, Rohde W, Stahl F, Strasburger CJ (1992). Synthesis of a cortisol-biotin conjugate and evaluation as a tracer in an immunoassay for salivary cortisol measurement. J Steroid Biochem Mol Biol 43: 683-692.
12. Endres CJ, Swaminathan S, DeJesus OT, Sievert M, Ruoho AE, Murali D et al (1997). Affinities of dopamine analogs for monoamine granular and plasma membrane transporters: implications for PET dopamine studies. Life Sci 60: 2399-2406.
13. Gallezot JD, Beaver JD, Gunn RN, Nabulsi N, Weinzimmer D, Singhal T et al (2012). Affinity and selectivity of [11C]-(\+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. Synapse 66: 489-500.
14. Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P et al (2006). Binding characteristics and sensitivity to endogenous dopamine of [11C]-(\+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem 97: 1089-1103.
15. Ginovart N, Tournier BB, Moulin-Sallanon M, Steimer T, Ibanez V, Millet P (2012). Chronic delta(9)-tetrahydrocannabinol exposure induces a sensitization of dopamine D(2/3) receptors in the mesoaccumbens and nigrostriatal systems. Neuropsychopharmacology 37: 2355-2367.
16. Ginovart N, Willeit M, Rusjan P, Graff A, Bloomfield PM, Houle S et al (2007). Positron emission tomography quantification of [11C]-(\+)-PHNO binding in the human brain. J Cereb Blood Flow Metab 27: 857-871.
17. Gruber AJ, Pope HG Jr. (2002). Marijuana use among adolescents. Pediatr Clin North Am 49: 389-413.
18. Gunn RN, Gunn SR, Turkheimer FE, Aston JA, Cunningham VJ (2002). Positron emission tomography compartmental models: a basis pursuit strategy for kinetic modeling. J Cereb Blood Flow Metab 22: 1425-1439.
19. Heishman SJ, Singleton EG (2006). Assessment of cannabis craving using the Marijuana Craving Questionnaire. Methods Mol Med 123: 209-216.
20. Ikemoto S, Panksepp J (1999). The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Brain Res Brain Res Rev 31: 6-41.
21. Kleber HD, Dupont RL (2012). Physicians and medical marijuana. Am J Psychiatry 169: 564-568.
22. Lederbogen F, Kirsch P, Haddad L, Streit F, Tost H, Schuch P et al 2011). City living and urban upbringing affect neural social stress processing in humans. Nature 474: 498-501.
23. Martinez D, Gil R, Slifstein M, Hwang DR, Huang Y, Perez A et al (2005). Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry 58: 779-786.
24. Martinez D, Narendran R, Foltin RW, Slifstein M, Hwang DR, Broft A et al (2007). Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry 164: 622-629.
25. Martinez D, Saccone PA, Liu F, Slifstein M, Orlowska D, Grassetti A et al (2012). Deficits in dopamine D(2) receptors and presynaptic dopamine in heroin dependence: commonalities and differences with other types of addiction. Biol Psychiatry 71: 192-198.
26. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y et al (2003). Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamineinduced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 23: 285-300.
27. Mathers DC, Ghodse AH (1992). Cannabis and psychotic illness. Br J Psychiatry 161: 648-653.
28. McRae-Clark AL, Carter RE, Price KL, Baker NL, Thomas S, Saladin ME et al 2011). Stress-and cue-elicited craving and reactivity in marijuana-dependent individuals. Psychopharmacology (Berl) 218: 49-58.
29. Menezes PR, Johnson S, Thornicroft G, Marshall J, Prosser D, Bebbington P et al (1996). Drug and alcohol problems among individuals with severe mental illness in south London. Br J Psychiatry 168: 612-619.
30. Mizrahi R, Addington J, Rusjan PM, Suridjan I, Ng A, Boileau I et al (2012). Increased stress-induced dopamine release in psychosis. Biol Psychiatry 71: 561-567.
31. Moore BA, Budney AJ (2003). Relapse in outpatient treatment for marijuana dependence. J Subst Abuse Treat 25: 85-89.
32. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M et al (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370: 319-328.
33. Murray AM, Ryoo HL, Gurevich E, Joyce JN (1994). Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci USA 91: 11271-11275.
34. Narendran R, Slifstein M, Guillin O, Hwang Y, Hwang DR, Scher E et al (2006a). Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(\+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 60: 485-495.
35. Narendran R, Slifstein M, Guillin O, Hwang Y, Hwang DR, Scher E et al (2006b). Dopamine (D(2/3)) receptor agonist positron emission tomography radiotracer [(11)C]-(\+)-PHNO is a D(3) receptor preferring agonist in vivo. Synapse 60: 485-495.
36. Parker G, Tupling H, Brown LB (1979). A parental bonding instrument. Br J Med Psychol 52: 1-10.
37. Pruessner JC, Champagne F, Meaney MJ, Dagher A (2004). Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C]raclopride. J Neurosci 24: 2825-2831.
38. Pruessner JC, Kirschbaum C, Meinlschmid G, Hellhammer DH (2003). Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. Psychoneuroendocrinology 28: 916-931.
39. Rabiner EA, Laruelle M (2010). Imaging the D3 receptor in humans in vivo using [11C](\+)-PHNO positron emission tomography (PET). Int J Neuropsychopharmacol 1-2.
40. Rabiner EA, Slifstein M, Nobrega J, Plisson C, Huiban M, Raymond R et al (2009). in vivo quantification of regional dopamine-D3 receptor binding potential of (\+)-PHNO: Studies in non-human primates and transgenic mice. Synapse 63: 782-793.
41. Read J, van Os J, Morrison AP, Ross CA (2005). Childhood trauma, psychosis and schizophrenia: a literature review with theoretical and clinical implications. Acta Psychiatr Scand 112: 330-350.
42. Robinson TE, Berridge KC (2000). The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 95(Suppl 2): S91-117.
43. Rusjan P, Mamo D, Ginovart N, Hussey D, Vitcu I, Yasuno F et al (2006). An automated method for the extraction of regional data from PET images. Psychiatry Res 147: 79-89.
44. Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, Slifstein M et al (2010). Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry 68: 392-399.
45. Sevy S, Smith GS, Ma Y, Dhawan V, Chaly T, Kingsley PB et al (2008). Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography. Psychopharmacology (Berl) 197: 549-556.
46. Shotbolt P, Tziortzi AC, Searle GE, Colasanti A, van der Aart J, Abanades S et al (2012). Within-subject comparison of [(11)C]-(\+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans. J Cereb Blood Flow Metab 32: 127-136.
47. Sinha R 2011). New findings on biological factors predicting addiction relapse vulnerability. Curr Psychiatry Rep 13: 398-405.
48. Sinha R, Fox HC, Hong KI, Hansen J, Tuit K, Kreek MJ 2011). Effects of adrenal sensitivity, stress-and cue-induced craving, and anxiety on subsequent alcohol relapse and treatment outcomes. Arch Gen Psychiatry 68: 942-952.
49. Spielberger CD, Gorusch RL, Lushene R, Vagg PR, Jacobs GA (1983). Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press: Palo Alto, CA.
50. Stokes P, Curran V, Grasby P (2008). Effects of THC on dopamine release in the human striatum: An 11C-raclopride PET study. Biol Psychiatry 63(7, Suppl. S): 127S-127S.
51. Stokes PR, Egerton A, Watson B, Reid A, Lappin J, Howes OD et al (2012). History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability. J Psychopharmacol 26: 144-149.
52. Suplita RL 2nd, Eisenstein SA, Neely MH, Moise AM, Hohmann AG (2008). Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia. Neuropharmacology 54: 161-171.
53. Suridjan I, Boileau I, Bagby M, Rusjan PM, Wilson AA, Houle S et al (2012). Dopamine response to psychosocial stress in humans and its relationship to individual differences in personality traits. J Psychiatr Res 46: 890-897.
54. Tanda G, Pontieri FE, Di Chiara G (1997). Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276: 2048-2050.
55. Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD, Jenkinson M et al 2011). Imaging dopamine receptors in humans with [11C]-(\+)-PHNO: dissection of D3 signal and anatomy. Neuroimage 54: 264-277.
56. Urban NB, Slifstein M, Thompson JL, Xu X, Girgis RR, Raheja S et al (2012). Dopamine release in chronic cannabis users: a [11c]raclopride positron emission tomography study. Biol Psychiatry 71: 677-683.
57. van Leeuwen AP, Creemers HE, Greaves-Lord K, Verhulst FC, Ormel J, Huizink AC 2011). Hypothalamic-pituitary-adrenal axis reactivity to social stress and adolescent cannabis use: the TRAILS study. Addiction 106: 1484-1492.
58. van Os J, Kenis G, Rutten BP 2011). The environment and schizophrenia. Nature 468: 203-212.
59. Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M et al (2001). Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21: 9414-9418.
60. Volkow ND, Fowler JS, Wang GJ, Hitzemann R, Logan J, Schlyer DJ et al (1993). Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 14: 169-177.
61. Volkow ND, Wang GJ, Fowler JS, Logan J, Hitzemann R, Ding YS et al (1996). Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin Exp Res 20: 1594-1598.
62. Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG (2001). Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res 107: 173-177.
63. Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D et al (2005). Radiosynthesis and evaluation of [11C]-(\+)-4-propyl-3,4,4a,5,6,10b- hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 48: 4153-4160.